1-5 of 5
Larissa Ferreira Lucas
Close
Sort by
Journal Articles

Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS

Edvan De Queiroz Crusoe, Joanna Leal, Juliana Andrade Santos, Herbert Henrique de Melo Santos, Allan de souza Santos, Larissa Ferreira Lucas, Alessandro de M. Almeida, Marcos Chaves, Daniela Dourado Dutra, Vania T.M. Hungria, Marco Aurelio Salvino, Maria da Gloria B. Arruda
Journal: Blood
Blood (2022) 140 (Supplement 1): 7699–7700.
https://doi.org/10.1182/blood-2022-164866
Published: 2022
Journal Articles

Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients

Edvan De Queiroz Crusoe, Joanna Leal, Marco Aurelio Salvino, Larissa Ferreira Lucas, Juliana Andrade Santos, Herbert Henrique de Melo Santos, Alessandro de M. Almeida, Allan de souza Santos, Marcos Chaves, Mariane Melo Santos, Sarah Queiroz Silva, Lucas de Oliveira Vieira, Cleverson Alves Fonseca, Elisangela Adorno, Vania Hungria, Maria da Gloria B. Arruda
Journal: Blood
Blood (2021) 138 (Supplement 1): 3943.
https://doi.org/10.1182/blood-2021-150607
Published: 2021
Journal Articles

First Description of Upfront Target Therapy Treating AML and Bcll Presented Simultaneously As First Line

Juliana Santos Carvalho, MD, Anna Flávia Silva Alves Silva, MD, Maysa Coité Silva, MD, Itala Gomes Santos, MD, Laryssa Pinto Aragão, MD, Larissa Ferreira Lucas, MD, Herbert Henrique de Melo Santos, MD, Mônica Botura, MD, Alex Nano Magalhães Rêgo, MD, Maria da Gloria B. Arruda, MD PhD, Edvan De Queiroz Crusoe, MDPhD, Alessandro de M. Almeida, MD, Renata Alves, MD, Marianna Batista Vieira Lima, MD, Victor Oliveira Sousa Guimarães, MD, Marco Aurelio Salvino, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-143224
Published: 2020
Journal Articles

Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results

Allan de souza Santos, BS, Herbert Henrique de Melo Santos, MD, Marco Aurelio Salvino, MD PhD, Sarah Queiroz Silva, MD, Larissa Ferreira Lucas, MD, Alessandro de M. Almeida, MD, Mariane Melo Santos, BS, MsC, Juliana Andrade Santos, MD, Vania T. M. Hungria, MD PhD, Maria da Gloria B. Arruda, MD PhD, Alex Torres, PhD, Edvan De Queiroz Crusoe, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-141438
Published: 2020
Journal Articles

Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients

Edvan De Queiroz Crusoe, MDPhD, Marco Aurelio Salvino, MD PhD, Sarah Queiroz Silva, MD, Herbert Henrique de Melo Santos, MD, Allan de souza Santos, BS, Alessandro de M. Almeida, MD, Lucas de Oliveira Vieira, MD, Cleverson Alves Fonseca, Pham, Larissa Ferreira Lucas, MD, Joanna Leal, MD, Mariane Melo Santos, BS, MsC, Juliana Andrade Santos, MD, Elisangela Adorno, Pham, PhD, Vania T. M. Hungria, MD PhD, Maria da Gloria B. Arruda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-138873
Published: 2020